Quest for Discovering Novel CDK12 Inhibitor by Leveraging High-Throughput Virtual Screening
Authors:
Preprint
- 29 September 2023
- preprint
- Published by Springer Nature in Research Square
Abstract
CDK12 is essential for cellular processes like RNA processing, transcription, and cell cycle regulation, inhibiting cancer cell growth and facilitating macrophage invasion. CDK12 is a significant oncogenic factor in various cancers, including HER2-positive breast cancer, Anaplastic thyroid carcinoma, Hepatocellular carcinoma, prostate cancer, and Ewing sarcoma. It is also regarded as a potential biomarker, emphasizing its broader significance in oncology. Targeting CDK12 offers a promising strategy to develop therapy. Various monoclonal antibodies have drawn wide attention, but they are expensive compared to small-molecule inhibitors, limiting their accessibility and affordability for patients. Thus, in this research, we have tried to identify potent CDK12 inhibitors by employing extensive high-throughput virtual screening. RASPD protocol has been employed to screen three different databases against the target followed by drug-likeness, molecular docking, ADME, toxicity, Consensus molecular docking, and MD Simulation. The research conducted yielded one compound that have demonstrated robust binding affinity, favorable ADME features, little toxicity, and exceptional stability. The promotion of cancer cell death can be achieved by inhibiting CDK12 using this compound that have been identified.Keywords
All Related Versions
This publication has 78 references indexed in Scilit:
- Lessons Learned in Empirical Scoring with smina from the CSAR 2011 Benchmarking ExerciseJournal of Chemical Information and Modeling, 2013
- lazar: a modular predictive toxicology frameworkFrontiers in Pharmacology, 2013
- Ewing's sarcomaThe Lancet Oncology, 2010
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibilityJournal of Computational Chemistry, 2009
- The complexity of genotypic alterations underlying HER2-positive breast cancer: an explanation for its clinical heterogeneityCurrent Opinion in Oncology, 2007
- Comparison of Consensus Scoring Strategies for Evaluating Computational Models of Protein−Ligand ComplexesJournal of Chemical Information and Modeling, 2005
- UCSF Chimera—A visualization system for exploratory research and analysisJournal of Computational Chemistry, 2004
- The Protein Data BankActa Crystallographica Section D Structural Biology, 2002
- Molecular Properties That Influence the Oral Bioavailability of Drug CandidatesJournal of Medicinal Chemistry, 2002
- Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1Advanced Drug Delivery Reviews, 2001